Pharmacology and Treatment
Infliximab for the Treatment of Hidradenitis SuppurativaFernández-Vozmediano J.M. · Armario-Hita J.C.
Department of Dermatology, University Hospital of Puerto Real, University of Cádiz, Cádiz, Spain
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Introduction: Hidradenitis suppurativa is a chronic inflammatory disease characterized by significant morbidity. Current medical therapies are usually only minimally effective. Objective: To assess the efficacy and safety of infliximab monotherapy for the treatment of severe extensive refractory forms of hidradenitis suppurativa. Design: A retrospective study in a group of 6 patients who received treatment with infliximab for hidradenitis suppurativa, in the Dermatology Department of the University Hospital of Puerto Real in the last year. The dose was 5–10 mg/kg at weeks 0, 2 and 6, followed by a maintenance dose every 4 weeks. Subjective and objective efficacy was assessed before and after each treatment session. Results: All patients experienced improvement in subjective symptoms after the initial dose. A decrease in exudation, the size and number of lesions and less development of fistulous tracts were observed. The patients were followed up during 6 months. Treatment was generally well tolerated and there was only one mild reaction to the infusion in the form of headache. No patient required treatment discontinuation due to adverse effects. Conclusions: Infliximab was shown to be an effective therapeutic alternative for severe extensive forms of hidradenitis suppurativa when it is used as monotherapy.
© 2007 S. Karger AG, Basel
Kornbluth A: Infliximab approved for use in Crohn’s disease: a report on the FDA GI Advisory Committee conference. Inflamm Bowel Dis 1999;340:253–259.
- Maini RN, Breedveld FD, Kalden JR, et al: Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552–1563.
- Antoni CE, Kavanaugh A, Kirkham B, et al: Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 2005;52:1227–1236.
- Reich K, Nestle FO, Papp K, et al, EXPRESS study investigators: Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005;366:1367–1374.
- Roy MK, Appleton MS, Delicata RJ, et al: Probable association between hidradenitis suppurativa and Crohn’s disease: significance of epithelioid granuloma. Br J Surg 1997;84:375–376.
- Elliot MJ, Maini RN, Feldmann M, et al: Randomized double blind comparison of chimeric monoclonal antibody to tumor necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105–1110.
- Martínez F, Nos P, Benlloch S, Ponce J: Hidradenitis suppurativa and Crohn’s disease: response to treatment with infliximab. Inflamm Bowel Dis 2001;7:323–326.
- Katsanos KH, Christodoulou DK, Tsianos EV: Axillary hidradenitis suppurativa successfully treated with infliximab in a Crohn’s disease patient. Am J Gastroenterol 2002;97:2155–2156.
- Lebwohl B, Sapadin AN: Infliximab for the treatment of hidradenitis suppurativa. J Am Acad Dermatol 2003;49:S275–S276.
- Adams DR, Gordon KB, Devenyi AG, Ioffreda MD: Severe hidradenitis suppurativa treated with infliximab infusion. Arch Dermatol 2003;139:1540–1542.
- Sullivan TP, Welsh E, Kerdel FA, et al: Infliximab for hidradenitis suppurativa. Br J Dermatol 2003;149:1046–1049.
- Cusack C, Buckley C: Etanercept: effective in the management of hidradenitis suppurativa. Br J Dermatol 2006;154:726–729.
- Moul DK, Korman NJ: The cutting edge: severe hidradenitis suppurativa treated with adalimumab. Arch Dermatol 2006;142:1110–1112.
- Sartorius K, Lapins J, Jalal S, et al: Bacteraemia in patients with hidradenitis suppurativa undergoing carbon dioxide laser surgery: detection and quantification of bacteria by lysis-filtration. Dermatology 2006;213:305–312.
- Thielen AM, Kuenzli S, Saurat JH: Cutaneous adverse events of biological therapy for psoriasis: review of the literature. Dermatology 2005;211:209–217.
- Thielen AM, Barde C, Saurat JH: Long-term infliximab for severe hidradenitis suppurativa. Br J Dermatol 2006;155:1105–1107.
- Pirard D, Arco D, Debrouckere V, Heenen M: Anti-tumor necrosis factor alpha-induced psoriasiform eruptions: three further cases and current overview. Dermatology 2006;213:182.
- Ramírez-Hernández M, Marras C, Martínez-Escribano JA: Infliximab-induced vitiligo. Dermatology 2005;210:79–80.
Maalouf E, Faye O, Poli F, et al: Fatal epidermoid carcinoma in hidradenitis suppurativa following treatment with infliximab. Ann Dermatol Vénéréol 2006;133:473–474.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.